基于扩增子的血浆cfDNA二代测序检测晚期NSCLC驱动与耐药突变
该研究评估基于扩增子的血浆二代测序(NGS)在晚期非小细胞肺癌(NSCLC)中检测驱动和耐药突变的性能。46例患者168份血浆样本的分析显示,血浆NGS与ddPCR等位基因分数高度一致(R2=0.95),EGFR驱动突变检测灵敏度100%,ALK/ROS1融合检出率89%,并可检出多种奥希替尼耐药机制。
要点
- 血浆扩增子NGS与ddPCR检测变异等位基因分数高度一致(R2=0.95)。
- EGFR驱动突变检测灵敏度100%,优于ddPCR的87%。
- 可检出ALK/ROS1融合及奥希替尼多种耐药机制,包括治疗前或进展前数月。
核心结论
- 基于扩增子的血浆NGS能以高准确度检测NSCLC全线可靶向基因型,包括融合基因。
- 血浆NGS可检出多种原有和获得性耐药机制,有望替代单突变数字PCR用于TKI耐药后个体化治疗。
研究设计与样本
- 研究纳入已知可靶向基因型(EGFR、ALK/ROS1及其他罕见基因型)的NSCLC患者,采集治疗期间血浆样本,对肿瘤基因型设盲分析。
- 血浆NGS采用增强标签扩增子测序,覆盖36个基因的热点与编码区,并包含内含子区域以检测ALK/ROS1融合。
- 诊断准确性对比血浆微滴数字PCR(ddPCR)及肿瘤基因型。
- 共研究46例患者的168份样本。
主要发现
- 80份样本中120个变异配对比较血浆NGS与ddPCR,等位基因分数高度一致(R2=0.95)。
- 治疗前血浆NGS检测EGFR驱动突变灵敏度为100%(30/30),ddPCR为87%(26/30)。
- 可检测全线罕见驱动致癌突变,包括ALK/ROS1融合检出8/9(89%)。
- 25例对奥希替尼耐药的EGFR T790M阳性患者中,检出15种耐药机制,包括三级EGFR突变(C797S、Q791P)及非EGFR基因突变或扩增。
- 部分耐药机制可在治疗前或进展前数月检出。
临床怎么用
- 血浆扩增子NGS可用于晚期NSCLC可靶向基因型(含融合)的检测。
- 可用于EGFR TKI耐药后耐药机制的动态监测。
局限性
- 研究样本量有限(46例患者、168份样本),需更大队列验证。
- 为设盲分析,非前瞻性干预性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Genomic analysis of plasma cell-free DNA is transforming lung cancer care; however, available assays are limited by cost, turnaround time, and imperfect accuracy. Here, we study amplicon-based plasma next-generation sequencing (NGS), rather than hybrid-capture-based plasma NGS, hypothesizing this would allow sensitive detection and monitoring of driver and resistance mutations in advanced non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: Plasma samples from patients with NSCLC and a known targetable genotype (EGFR, ALK/ROS1, and other rare genotypes) were collected while on therapy and analyzed blinded to tumor genotype. Plasma NGS was carried out using enhanced tagged amplicon sequencing of hotspots and coding regions from 36 genes, as well as intronic coverage for detection of ALK/ROS1 fusions. Diagnostic accuracy was compared with plasma droplet digital PCR (ddPCR) and tumor genotype. RESULTS: A total of 168 specimens from 46 patients were studied. Matched plasma NGS and ddPCR across 120 variants from 80 samples revealed high concordance of allelic fraction (R2 = 0.95). Pretreatment, sensitivity of plasma NGS for the detection of EGFR driver mutations was 100% (30/30), compared with 87% for ddPCR (26/30). A full spectrum of rare driver oncogenic mutations could be detected including sensitive detection of ALK/ROS1 fusions (8/9 detected, 89%). Studying 25 patients positive for EGFR T790M that developed resistance to osimertinib, 15 resistance mechanisms could be detected including tertiary EGFR mutations (C797S, Q791P) and mutations or amplifications of non-EGFR genes, some of which could be detected pretreatment or months before progression. CONCLUSIONS: This blinded analysis demonstrates the ability of amplicon-based plasma NGS to detect a full range of targetable genotypes in NSCLC, including fusion genes, with high accuracy. The ability of plasma NGS to detect a range of preexisting and acquired resistance mechanisms highlights its potential value as an alternative to single mutation digital PCR-based plasma assays for personalizing treatment of TKI resistance in lung cancer.
引用
- Guibert N, Hu Y, Feeney N, et al. Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer. Ann Oncol. 2018. PMID: 29325035. doi:10.1093/annonc/mdy005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。